PACIRA BIOSCIENCES, INC. Asset Retirement Obligation, Liabilities Settled
PACIRA BIOSCIENCES, INC. (PCRX) reported Asset Retirement Obligation, Liabilities Settled of $292.00 thousand for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Notes › Asset Retirement Obligations
us-gaap:AssetRetirementObligationLiabilitiesSettled · last filed 2020-05-07
- PACIRA BIOSCIENCES, INC. asset retirement obligation, liabilities settled for the quarter ending 2020-03-31 was $292.00K, a 311.27% increase year-over-year.
- PACIRA BIOSCIENCES, INC. asset retirement obligation, liabilities settled for the quarter ending 2019-12-31 was $97.00K, a 870.00% increase year-over-year.
- PACIRA BIOSCIENCES, INC. asset retirement obligation, liabilities settled for the quarter ending 2019-09-30 was $151.00K, a 202.00% increase year-over-year.
- PACIRA BIOSCIENCES, INC. asset retirement obligation, liabilities settled for the quarter ending 2019-06-30 was $85.00K, a 372.22% increase year-over-year.
- PACIRA BIOSCIENCES, INC. asset retirement obligation, liabilities settled for fiscal 2019 was $404.00K, a 343.96% increase from fiscal 2018.
- PACIRA BIOSCIENCES, INC. asset retirement obligation, liabilities settled for fiscal 2018 was $91.00K, a 78.33% decline from fiscal 2017.
- PACIRA BIOSCIENCES, INC. asset retirement obligation, liabilities settled for fiscal 2017 was $420.00K.
| Period end | Asset Retirement Obligation, Liabilities Settled 3 month | Asset Retirement Obligation, Liabilities Settled 6 month | Asset Retirement Obligation, Liabilities Settled 9 month | Asset Retirement Obligation, Liabilities Settled 12 month |
|---|---|---|---|---|
| 2020-03-31 | $292.00K 10-Q · filed 2020-05-07 | $389.00K derived: sum of 2 quarters · filed 2020-05-07 | $540.00K derived: sum of 3 quarters · filed 2020-05-07 | $625.00K derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | $97.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $248.00K derived: sum of 2 quarters · filed 2020-02-21 | $333.00K derived: sum of 3 quarters · filed 2020-02-21 | $404.00K 10-K · filed 2020-02-21 |
| 2019-09-30 | $151.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $236.00K derived: sum of 2 quarters · filed 2019-11-08 | $307.00K 10-Q · filed 2019-11-08 | $317.00K derived: sum of 4 quarters · filed 2020-02-21 |
| 2019-06-30 | $85.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $156.00K 10-Q · filed 2019-08-08 | $166.00K derived: sum of 3 quarters · filed 2020-02-21 | $216.00K derived: sum of 4 quarters · filed 2020-02-21 |
| 2019-03-31 | $71.00K 10-Q · filed 2019-05-02 | $81.00K derived: sum of 2 quarters · filed 2020-02-21 | $131.00K derived: sum of 3 quarters · filed 2020-02-21 | $149.00K derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $60.00K derived: sum of 2 quarters · filed 2020-02-21 | $78.00K derived: sum of 3 quarters · filed 2020-02-21 | $91.00K 10-K · filed 2020-02-21 |
| 2018-09-30 | $50.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $68.00K derived: sum of 2 quarters · filed 2018-11-01 | $81.00K 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $31.00K 10-Q · filed 2018-08-02 | ||
| 2018-03-31 | $13.00K 10-Q · filed 2018-05-03 | |||
| 2017-12-31 | $420.00K 10-K · filed 2020-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |